Skip to main content
SpringerLink
Log in

Asthma and Allergic Diseases

  • Chapter
National Institute of Allergy and Infectious Diseases, NIH

Part of the book series: Infectious Disease ((ID))

  • 1199 Accesses

Although not all cases of asthma or rhinitis are clearlyattributable to atopy, it is accepted that atopy does play an etiologic role in the pathophysiology of these conditions (1). The reported proportion of asthma and rhinitis cases attributed to atopy varies among studies and populations. The attributable risk is also highly dependent on whether researchers use a more or less conservative definition of atopy. Researchers who have reviewed this literature to calculate the weighted mean population attributable risk suggest that approximately 40% of asthma cases and 50% of noninfectious rhinitis cases can be attributed to atopy (2,3). Additionally, atopy is one of the strongest currently identified predisposing factors for the development of asthma (4,5). In light of the common pathophysiologic basis for allergic asthma and allergic rhinitis, it is not surprising that these conditions often coexist. This has led researchers to postulate that these conditions may actually be manifestations of one syndrome (1,6)

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Belliveau, P. P. (2005) Omalizumab: a monoclonal anti-IgE antibody, Med. Gen. Med., 7(1), 27.

    Google Scholar 

  2. Pearce, N., Pekkanen, J., and Beasley, R. (1999) How much asthma is really attributable to atopy? Thorax, 54, 268–272.

    Article  PubMed  CAS  Google Scholar 

  3. Zacharasiewicz, A., Douwes, J., and Pearce, N. (2003) What proportion of rhinitis symptoms is attributable to atopy? J. Clin. Epidemiol., 56, 385–390.

    Article  PubMed  Google Scholar 

  4. National Asthma Education and Prevention Program. Expert panel report: Guidelines for the diagnosis and management of asthma. Updated selected topics-2002, J. Allergy Clin. Immunol., 110(Part 2), S141–S219.

    Google Scholar 

  5. Baroody, F. M. (2003) Allergic rhinitis: broader disease effects and implications for management, Otolaryngol. Head Neck Surg., 128, 616–631.

    Article  PubMed  Google Scholar 

  6. Togias, A. (2003) Rhinitis and asthma: evidence for respiratory system integration, J. Allergy Clin. Immunol., 111, 1171–1183.

    Article  PubMed  Google Scholar 

  7. Goldsby, R. A., Kindt, T. J., Osborne, B. A., and Kuby, J. (eds.) (2003) Immunology, 5th ed., W. H. Freeman and Company, New York.

    Google Scholar 

  8. Tarlinton, D. (1997) Enhanced: antigen presentation by memory B cells – the sting is in the tail, Science, 276, 374–375.

    Article  PubMed  CAS  Google Scholar 

  9. Hook, W. A., Zinsser, F. U., Berenstein, E. H., and Siraganian, R. P. (1991) Monoclonal antibodies defining epitopes on human IgE, Mol. Immunol., 28, 631–639.

    Article  PubMed  CAS  Google Scholar 

  10. Presta, L., Shields, R., O’Connell, L., et al. (1994) The binding site on human immunoglobulin E for its high affinity receptor, J. Biol. Chem., 269, 26368–26373.

    PubMed  CAS  Google Scholar 

  11. Nissim, A., Schwarzbaum, S., Siraganian, R., and Eshhar, Z. (1993) Fine specificity of the IgE interaction with the low and high affinity Fc receptor, J. Immunol., 150, 1365–1374.

    PubMed  CAS  Google Scholar 

  12. Bousquet, J., Van Cauwenberge, P., Khaltaev, N. (2001) Aria Workshop Group. Allergic rhinitis and its impact on asthma, J. Allergy Clin. Immunol., 108(Suppl), S147–S334.

    Article  PubMed  CAS  Google Scholar 

  13. Oettgen, H. C. and Geha, R. S. (1999) IgE in asthma and atopy: cellular and molecular connections, J. Clin. Invest., 104, 829–835.

    Article  PubMed  CAS  Google Scholar 

  14. Broide, D. H. (2001) Molecular and cellular mechanisms of allergic disease, J. Allergy Clin. Immunol., 108, S65–S71.

    Article  PubMed  CAS  Google Scholar 

  15. Kay, A. B. (2001) Allergy and allergic diseases, N. Engl. J. Med., 344, 30–37.

    Article  PubMed  CAS  Google Scholar 

  16. Pearlman, D. S. (1999) Pathophysiology of the inflammatory response, J. Allergy Clin. Immunol., 104, S132–S137.

    Article  PubMed  CAS  Google Scholar 

  17. Novak, N., Kraft, S., and Bieber, T. (2001) IgE receptors, Curr. Opin. Immunol., 13, 721–726.

    Article  PubMed  CAS  Google Scholar 

  18. Gustavsson, S., Hjulstrom, S., Tianmin, L., and Heyman, B. (1994) CD23/IgE- mediated regulation of the specific antibody response in vivo, J. Immunol., 152, 4793–4800.

    PubMed  CAS  Google Scholar 

  19. Cohn, L., Elias, J. A., and Chupp, G. L. (2004) Asthma: mechanisms of disease persistence and progression, Annu. Rev. Immunol., 22, 789–815.

    Article  PubMed  CAS  Google Scholar 

  20. Davies, D. E., Wicks, J., Powell, R. M., Puddicombe, S. M., and Holgate, S. T. (2003) Airway remodeling in asthma: new insights, J. Allergy Clin. Immunol., 111, 215–225.

    Article  PubMed  CAS  Google Scholar 

  21. Cho, J. Y., Miller, M., Baek, K. J., Han, J. W., Nayar, J., Lee, S. Y., McElwain K., McElwain, S., Friedman, S., and Broide, D. H. (2004) Inhibition of airway remodeling in IL-5-deficient mice, J. Clin. Invest., 113, 551–560.

    PubMed  CAS  Google Scholar 

  22. Humbles, A. A., Lloyd, C. M., McMillan, S. J., Friend, D. S., Xanthou, G., et al. (2004) A critical role for eosinophils in allergic airways remodeling, Science, 305, 1776–1779.

    Article  PubMed  CAS  Google Scholar 

  23. Flood-Page, P., Menzies-Gow, A., Phipps, S., Ying, S., et al. (2003) Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics, J. Clin. Invest., 112, 1029–1036.

    PubMed  CAS  Google Scholar 

  24. Holgate, S. T., Davies, D. E., Lackie, P. M., Wilson, S. J., Puddicombe, S. M., and Lordan, J. L. (2000) Epithelial-mesenchymal interactions in the pathogenesis of asthma, J. Allergy Clin. Immunol., 105, 193–204.

    Article  PubMed  CAS  Google Scholar 

  25. Marth, J. D. (1996) Recent advances in gene mutagenesis by site-directed recombination, J. Clin. Invest., 97, 1999–2002.

    Article  PubMed  CAS  Google Scholar 

  26. Maeda, S., Chang, L., Li, Z. W., Luo, J. L., Leffert, H., and Karin, M. (2003) IKK beta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha, Immunity, 19, 725–737.

    Article  PubMed  CAS  Google Scholar 

  27. Li, Z. W., Omori, S. A., Labuda, T., Karin, M., and Rickert, R. C. (2003) IKK beta is required for peripheral B cell survival and proliferation, J. Immunol., 170, 4630–4637.

    PubMed  CAS  Google Scholar 

  28. Gilmore, T. D. (2006) Introduction To NF-ҝB: players, pathways, perspectives, Oncogene, 25, 6680–6684.

    Article  PubMed  CAS  Google Scholar 

  29. Broide, D., Lawrence, T., Doherty, T., et al. (2005) Allergen-induced peribronchial fibrosis and mucus production mediated by IҝB kinase β-dependent genes in airway epithelium, Proc. Natl. Acad. Sci. U.S.A., 102(49), 17423–17727.

    Article  CAS  Google Scholar 

  30. Bonizzi, G. and Karin, M. (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity, Trends Immunol., 25, 280–288.

    Article  PubMed  CAS  Google Scholar 

  31. Broide, D. H., Lotz, M., Cuomo, A. J., Coburn, D. A., Federman, E. C., and Wasserman, S. I. (1992) Cytokines in symptomatic asthma airways, J. Allergy Clin. Immunol., 89, 958–967.

    Article  PubMed  CAS  Google Scholar 

  32. Makris, C., Godfrey, G., Krähn-Senftleben, T., et al. (2000) Female mice heterozygous for IKK-γ/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti, Mol. Cell, 5, 969–979.

    Article  PubMed  CAS  Google Scholar 

  33. Dejardin, E., Droin, N., Delhase, M., et al. (2002) The lymphotoxin-β receptor induces different patterns of gene expression via two NF-ҝB pathways, Immunity, 17, 525–535.

    Article  PubMed  CAS  Google Scholar 

  34. Li, Z. W., Chu, W., Hu, Y., et al. (1999) The IKKβ subunit of IҝB kinase (IKK) is essential for nuclear factor ҝB activation and prevention of apoptosis, J. Exp. Med., 189, 1839–1845.

    Article  PubMed  CAS  Google Scholar 

  35. Chen, L. W., Egan, L., Li, Z.-W., et al. (2003) The two faces of IKK and NF-ҝB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion, Nat. Med., 9, 575–581.

    Article  PubMed  CAS  Google Scholar 

  36. Hu, Y., Baud, V., Delhase, M., et al. (1999) Abnormal morphogenesis but intact activation in mice lacking the IKKα subunit of IҝB kinase, Science, 284, 316–320.

    Article  PubMed  CAS  Google Scholar 

  37. Hu, Y., Baud, V., Oga, T., et al. (2001) IKKα controls formation of the epidermis independently of NF-ҝB, Nature, 410, 710–714.

    Article  PubMed  CAS  Google Scholar 

  38. Cao, Y., Bonizzi, G., Seagroves, T., et al. (2001) IKKα provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development, Cell, 107, 763–775.

    Article  PubMed  CAS  Google Scholar 

  39. Yamamoto, Y., Verma, U. N., Prajapati, S., Kwak, Y. T., and Gaynor, R. B. (2003) Histone H3 phosphorylation by IKK-α is critical for cytokine-induced gene expression, Nature, 423, 655–659.

    Article  PubMed  CAS  Google Scholar 

  40. Israel, A. (2003) Signal transduction: a regulator branches out, Nature, 423, 596–597 (2003).

    Google Scholar 

  41. Senftleben, U., Cao, Y., Xiao, G., et al. (2001) Activation by IKKα of a second, evolutionary conserved, NF-ҝB signaling pathway, Science, 293, 1495–1499.

    Article  PubMed  CAS  Google Scholar 

  42. Ghosh, S. and Karin, M. (2002) Missing pieces in the NF-ҝB puzzle, Cell, 109, S81–S96.

    Article  PubMed  CAS  Google Scholar 

  43. Karin, M. and Ben-Neriah, Y. (2000) Phosphorylation meets ubiquitination: the control of NF-ҝB activity, Annu. Rev. Immunol., 18, 621–663.

    Article  PubMed  CAS  Google Scholar 

  44. Yang, L., Cohn, L., Zhang, D. H., Homer, R., Ray, A., and Ray, P. (1998) Essential role of nuclear factor kappaB in the induction of eosinophilia in allergic airway inflammation, J. Exp. Med., 188, 1739–1750.

    Article  PubMed  CAS  Google Scholar 

  45. Das, J., Chen, C. H., Yang, L., Cohn, L., Ray, P., and Ray, A. (2001) A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation, Nat. Immunol., 2, 45–50.

    Article  PubMed  CAS  Google Scholar 

  46. Donovan, C. E., Mark, D. A., He, H. Z., Liou, H. C., Kobzik, L., et al. (1999) NF- kappa B/Rel transcription factors: c-Rel promotes airway hyperresponsiveness and allergic pulmonary inflammation, J. Immunol., 163, 6827–6833.

    PubMed  CAS  Google Scholar 

  47. Hart, L. A., Krishnan, V. L., Adcock, I. M., Barnes, P. J., and Chung, K. F. (1998) Activation and localization of transcription factor, nuclear factor-kappaB, in asthma, Am. J. Respir. Crit. Care Med., 158, 1585–1592.

    PubMed  CAS  Google Scholar 

  48. Gagliardo, R., Chanez, P., Mathieu, M., Bruno, A., Costanzo, G., et al. (2003) Persistent activation of nuclear factor-kappaB signaling pathway in severe uncontrolled asthma, Am. J. Respir. Crit. Care Med., 168, 1190–1198.

    Article  PubMed  Google Scholar 

  49. Poynter, M. E., Cloots, R., van Woerkom, T., Butnor, K. J., Vacek, P., et al. (2004) NF-kappa B activation in airways modulates allergic inflammation but not hyperresponsiveness, J. Immunol. 173, 7003–7009.

    PubMed  CAS  Google Scholar 

  50. Karin, M., Yamamoto, Y., and Wang, Q. M. (2004), The IKK NF-ҝB system: a treasure trove for drug development, Nat. Rev. Drug Discov., 3, 17–26.

    Article  PubMed  CAS  Google Scholar 

  51. Lenz, H. J. (2003) Clinical update: proteasome inhibitors in solid tumors, Cancer Treat. Rev., 29 (Suppl. 1), 41–48.

    Article  PubMed  CAS  Google Scholar 

  52. Li, Q., Van Antwerp, D., Mercurio, F., Lee, K. F., and Verma, I. M. (1999) Severe liver degeneration in mice lacking the IҝB kinase 2 gene, Science, 284, 321–325.

    Article  PubMed  CAS  Google Scholar 

  53. Kitagawa, M., Hatekeyama, S., Shirane, M., et al. (1999) An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of β-catenin, EMBO J., 18, 2401–2410.

    Article  PubMed  CAS  Google Scholar 

  54. Winston, J. T., Strack, P., Beer-Romero, P., Chu, C., Elledge, S. J., and Harper, J. W. (1999) The SCF-β-TRCP ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IҝBβ and B-catenin and stimulates IҝBα ubiquitination in vitro, Genes Dev., 13, 270–283.

    Article  PubMed  CAS  Google Scholar 

  55. Fuchs, S. Y., Chen, A., Xiong, Y., Pan, Z. Q., and Ronai, Z. (1999) HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IҝB and β-catenin, Oncogene, 18, 2039–2046.

    Article  PubMed  CAS  Google Scholar 

  56. Rubinfeld, B., Robbins, P., El-Gamil, M., et al. (1997) Stabilization of β-catenin by genetic defects in melanoma cell lines, Science, 275, 1790–1792.

    Article  PubMed  CAS  Google Scholar 

  57. Morin, P. J., Sparks, A. B. Korinek, V., et al. (1997) Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC, Science, 275, 1787–1790.

    Article  PubMed  CAS  Google Scholar 

  58. Kopp, E. and Ghosh, S. (1994) Inhibition of NF-ҝB by sodium salicylate and aspirin, Science, 265, 956–959.

    Article  PubMed  CAS  Google Scholar 

  59. Pierce, J. W., Read, M. A., Ding, H., Luscinskas, F. W., and Collins, T. (1996) Salicylates inhibit IҝBα phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration, J. Immunol., 156, 3961–3969.

    PubMed  CAS  Google Scholar 

  60. Yin, M.-J., Yamamoto, Y., and Gaynor, R. B. (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of IҝB kinase-β, Nature, 396, 77–80.

    Article  PubMed  CAS  Google Scholar 

  61. Yamamoto, Y., Yin, M.-J., Lin, K.-M., and Gaynor, R. B. (1999) Sulindac inhibits activation of the NF-ҝB pathway, J. Biol. Chem., 274, 27307–27314.

    Article  PubMed  CAS  Google Scholar 

  62. Berman, K. S., Verma, U. N., Harburg, G., et al. (2002) Sulindac enhances tumor necrosis factor-α-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-ҝB, Clin. Cancer Res., 8, 354–360.

    PubMed  CAS  Google Scholar 

  63. Yasui, H., Adachi, M., and Imai, K. (2003) Combination of tumor necrosis factor-α with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude mice, Cancer, 97, 1412–1420.

    Article  PubMed  CAS  Google Scholar 

  64. Wahl, C., Liptay, S., Adler, G., and Schmid, R. M. (1997) Sulfasalazine: a potent and specific inhibitor of NF-ҝB, J. Clin. Invest., 101, 1163–1174.

    Article  Google Scholar 

  65. Yan, F. and Polk, D. B. (1999) Aminosalicylic acid inhibits IҝB kinase-α phosphorylation of IҝBαI in mouse intestinal epithelial cells, J. Biol. Chem., 274, 36631–36636.

    Article  PubMed  CAS  Google Scholar 

  66. Egan, L. J., Mays, D. C., Huntoon, C. J., et al. (1999) Inhibition of interleukin-1- stimulated NF-ҝB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity, J. Biol. Chem., 274, 26448–26453.

    Article  PubMed  CAS  Google Scholar 

  67. Dredge, K., Dalgleish, A. G., and Marriott, J. B. (2003) Thalidomide analogs as emerging anti-cancer drugs, Anticancer Drugs 14, 331–335.

    Article  PubMed  CAS  Google Scholar 

  68. Keifer, J. A., Guttridge, D. C., Ashburner, B. P., and Baldwin, A. S., Jr. (2001) Inhibition of NF-ҝB activity by thalidomide through suppression of IҝB kinase activity, J. Biol. Chem., 276, 22382–22387.

    Article  PubMed  CAS  Google Scholar 

  69. Majumdar, S., Lamothe, B., and Aggarwal, B. B. (2002) Thalidomide suppresses NF-ҝB activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester, J. Immunol., 168, 2644–2651.

    PubMed  CAS  Google Scholar 

  70. Mitsiades, N., Mitsiadis, C. S., Poulaki, V., et al. (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications, Blood, 99, 4525–4530.

    Article  PubMed  CAS  Google Scholar 

  71. Gilroy, D. W., Colville-Nash, P. R., Willis, D., et al. (1999) Inducible cyclooxygenase may have anti-inflammatory properties, Nat. Med., 5, 698–701.

    Article  PubMed  CAS  Google Scholar 

  72. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., and Glass, C. K. (1998) The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation, Nature, 391, 79–82.

    Article  PubMed  CAS  Google Scholar 

  73. Rossi, A., Kapahi, P., Natoli, G., et al. (2000) Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IҝB kinase, Nature, 403, 103–108.

    Article  PubMed  CAS  Google Scholar 

  74. Straus, D. S., Pascual, G., Li, M., et al. (2000) 15-deoxy-D12,14-prostaglandin J2 inhibits multiple steps in the NF-ҝB signaling pathway, Proc. Natl Acad. Sci. U.S.A., 97, 4844–4849.

    Article  PubMed  CAS  Google Scholar 

  75. Lawrence, T., Gilroy, D. W., Colville-Nash, P. R., and Willoughby, D. A. (2001) Possible new role for NF-ҝB in the resolution of inflammation, Nat. Med., 7, 1291–1297.

    Article  PubMed  CAS  Google Scholar 

  76. Bowie, A. G. and O’Neill, L. A. (2000) Vitamin C inhibits NF-ҝB activation by TNF via the activation of p38 mitogen-activated protein kinase, J. Immunol., 165, 7180–7188.

    PubMed  CAS  Google Scholar 

  77. Carcamo, J. M., Pedraza, A., Borquez-Ojeda, O., and Golde, D. W. (2002) Vitamin C suppresses TNF-α-induced NF-ҝB activation by inhibiting IҝBα phosphorylation, Biochemistry, 41, 12995–13002.

    Article  PubMed  CAS  Google Scholar 

  78. Tsai, S. H., Liang, Y. C., Lin-Shiau, S. Y., and Lin, J. K. (1999) Suppression of TNFα-mediated NF-ҝB activity by myricetin and other flavonoids through downregulating the activity of IKK in ECV304 cells, J. Cell Biochem., 74, 606–615.

    Article  PubMed  CAS  Google Scholar 

  79. Holmes-McNary, M. and Baldwin, A. S., Jr. (2000) Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IҝB kinase, Cancer Res., 60, 3477–3483.

    PubMed  CAS  Google Scholar 

  80. Berlett, B. S. and Stadtman, E. R. (1997) Protein oxidation in aging, disease, and oxidative stress, J. Biol. Chem., 272, 20313–20316.

    Article  PubMed  CAS  Google Scholar 

  81. Hayakawa, M., Miyashita, H., Sakamoto, I., et al. (2003) Evidence that reactive oxygen species do not mediate NF-ҝB activation, EMBO J., 22, 3356–3366.

    Article  PubMed  CAS  Google Scholar 

  82. Sakon, S., Xue, X., Takekawa, M., et al. (2003) NF-ҝB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death, EMBO J., 22, 3898–3909.

    Article  PubMed  CAS  Google Scholar 

  83. Blackwell, T. S., Blackwell, T. R., Holden, E. P., Christman, B. W., and Christman, J. W. (1996) In vivo antioxidant treatment suppresses nuclear factor-ҝB activation and neutrophilic lung inflammation, J. Immunol., 157, 1630–1637.

    PubMed  CAS  Google Scholar 

  84. Anest, V., Hanson, J. L., Cogswell, P. C., et al. (2003) A nucleosomal function for IҝB kinase-α in NF-ҝB-dependent gene expression, Nature, 423, 659–663.

    Article  PubMed  CAS  Google Scholar 

  85. Signal Pharmaceuticals, Inc. (1999) Quinazoline analogs and related compounds and methods for treating inflammatory conditions. WO 199901441.

    Google Scholar 

  86. Leisten, J. C. et al. (2002) Identification of a disease modifying IKK2 inhibitor in rat adjuvant arthritis, Inflamm. Res., 51(Suppl. 2), A25.

    Google Scholar 

  87. Palanki, M. S., Gayo-Fung, L.M., Shevlin, G. I., et al. (2002) Structure–activity relationship studies of ethyl 2-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate: an inhibitor of AP-1 and NF-ҝB mediated gene expression, Bioorg. Med. Chem. Lett., 12, 2573–2577.

    Article  PubMed  CAS  Google Scholar 

  88. Aventis Pharma (2002) Preparation of substituted β-carbolines as potential therapeutics in diseases associated with increased IB kinase activity. WO 2001068648.

    Google Scholar 

  89. Castro, A. C., Dang, L. C., Soucy, F., et al. (2003) Novel IKK inhibitors: β- carbolines, Bioorg. Med. Chem. Lett., 13, 2419–2422.

    Article  PubMed  CAS  Google Scholar 

  90. Hideshima, T., Chauhan, D., Richardson, P., et al. (2003) NF-ҝB as a therapeutic target in multiple myeloma, J. Biol. Chem., 277, 16639–16647.

    Article  CAS  Google Scholar 

  91. Bristol-Myers Squibb Co. (2002) Method of treating inflammatory and immune diseases using 4-amino substituted imidazoquinoxaline, benzopyrazoloquinazoline, benzoimidazoquinoxaline and benzoimidazoquinoline inhibitors of IҝB kinase (IKK). WO 2002060386.

    Google Scholar 

  92. Burke, J. R., Pattoli, M. A., Gregor, K. R., et al. (2003) BMS-345541 is a highly selective inhibitor of IҝB kinase that binds at an allosteric site of the enzyme and blocks NF-ҝB-dependent transcription in mice, J. Biol. Chem., 278, 1450–1456.

    Article  PubMed  CAS  Google Scholar 

  93. McIntyre, K. W., Shuster, D. J., Gillooly, K. M., et al. (2003) A highly selective inhibitor of IҝB kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice, Arthritis Rheum., 48, 2652–2659.

    Article  PubMed  CAS  Google Scholar 

  94. Kishore, N., Sommers, C., Mathialagan, S., et al. (2003) A selective IKK-2 inhibitor blocks NF-ҝB-dependent gene expression in IL-1β stimulated synovial fibroblasts, J. Biol. Chem., 278, 32861–32871.

    Article  PubMed  CAS  Google Scholar 

  95. SmithKline Beecham Corp. (2002) Preparation of 2-aminothiophene-3-carboxamides as NF-ҝB inhibitors. WO 2002030353.

    Google Scholar 

  96. SmithKline Beecham Corp. (2003) NF-ҝB inhibitors. WO 2003029242.

    Google Scholar 

  97. AstraZeneca (2003) Preparation of ureido–carboxamido thiophene as inhibitors of IKK2 kinase. WO 2003010163.

    Google Scholar 

  98. AstraZeneca (2001) Preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2. WO 2001058890.

    Google Scholar 

  99. Roshak, A. K, Callahan, J. F., and Blake, S. M (2002) A small molecule inhibitor of IҝB kinase β (IKKβ) blocks inflammation and protects joint integrity in in vivo models of arthritis, Inflamm. Res. 51(Suppl. 2), S4.

    Google Scholar 

  100. Bayer (2002) Preparation of 2,4-diarylpyridines as IҝB kinase β inhibitors useful as antiinflammatories. WO 2002044153.

    Google Scholar 

  101. Bayer (2002) Preparation of hydroxyarylpyridines with IҝB kinase β (IKK) inhibiting activity. WO 2002024679.

    Google Scholar 

  102. Murata, T., Shimada, M., Sakakibara, S., et al. (2003) Discovery of novel and selective IKK-β serine-threonine protein kinase inhibitors. Part 1, Bioorg. Med. Chem. Lett., 13, 913–918.

    Article  PubMed  CAS  Google Scholar 

  103. Signal Pharmaceuticals, Inc. (2003) Preparation of anilinopyrimidines as IKK inhibitors. WO 2002046171.

    Google Scholar 

  104. Bayer (2003) Preparation of optically active pyridooxazinones as antiinflammatory agents. WO 2003076447.

    Google Scholar 

  105. Aventis Pharma (2001) Preparation of amino acid indolecarboxamides as modulators of NF-ҝB activity. WO 2001030774.

    Google Scholar 

  106. Aventis Pharma (2001) Preparation of benzimidazolecarboxylic acid amino acid amides as IҝB kinase inhibitors. WO 2001000610.

    Google Scholar 

  107. Pharmacia Corp. (2003) Preparation of pyrazolo [4,3-c] quinolines, chromeno[4,3-c]pyrazoles, and analogs for treatment of inflammation. WO 2003024936.

    Google Scholar 

  108. Pharmacia Corp. (2003) Preparation of 4,5-dihydro-1H-benzo[g]indazole-3-carboxamides for treatment of inflammation. WO 2003024935.

    Google Scholar 

  109. Tularik Inc. (2002) Preparation of imidazolylquinolinecarboxaldehyde semicarbazones as IKK modulators. WO 2002041843.

    Google Scholar 

  110. SmithKline Beecham Corp. (2002) Preparation of 5-amino-1H-imidazole-4-carboxamides as NF-ҝB inhibitors. WO 200230423.

    Google Scholar 

  111. Leo Pharma (2002) A method using cyanoguanidine compounds for modulating NF-ҝB activity and use for the treatment of cancer. WO 2002094265.

    Google Scholar 

  112. Leo Pharma (2002) Antitumor drug–cyanoguanidine IKK inhibitor combination. WO 2002094322.

    Google Scholar 

  113. Schou, C., Ottose, E. R., Petersen H. J., et al. (1997) Novel cyanoguanidines with potent oral antitumour activity, Bioorg. Med. Chem. Lett., 7, 3095–3100.

    Article  CAS  Google Scholar 

  114. Hjarnaa, P. J., Jonsson, E., Latini, S., et al. (1999) CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo, Cancer Res. 59, 5751–5157.

    Google Scholar 

  115. Martinsson, P., Ekelund, S., Nygren, P., et al. (2002) The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro – from cytotoxic synergy to complete inhibition of apoptosis, Br. J. Pharmacol., 137, 568–573.

    Article  PubMed  CAS  Google Scholar 

  116. Isis Pharmaceuticals, Inc. (2000) Antisense modulation of inhibitor-ҝ B kinase-β gene expression. WO 2000031105.

    Google Scholar 

  117. Takaesu, G., Sarabhi, R. M., Park, K.-J., et al. (2003) TAK1 is critical for IҝB kinase-mediated activation of the NF-ҝB pathway, J. Mol. Biol., 326, 105–115.

    Article  PubMed  CAS  Google Scholar 

  118. May, M. J. and Ghosh, S. (2002) Anti-inflammatory compounds and uses thereof. A cell-permeable peptide encompassing NEMO binding domain of IҝB kinase was able to not only inhibit TNFα-induced NF-ҝB activation but also reduce expression of E-selectin, an NF-ҝB-dependent target gene, in primary human endothelial cells. WO 2002156000.

    Google Scholar 

  119. May, M., D’Acquisto, F., Madge, L. A., et al. (2000) Selective inhibition of NF-ҝB activation by a peptide that blocks the interaction of NEMO with the IҝB kinase complex, Science, 289, 1550–1554.

    Article  PubMed  CAS  Google Scholar 

  120. Malveaux, F. J., Conroy, M. C., Adkinson, N. F., Jr., and Lichtensterin, L. M. (1978) IgE receptors on human basophils. Relationship to serum IgE concentration, J. Clin. Invest., 62, 176–181.

    Article  PubMed  CAS  Google Scholar 

  121. MacGlashan, D., McKenzie-White, J., Chichester, K., et al. (1998) In vitro regulation of FcepsilonRIalpha expression on human basophils by IgE antibody, Blood, 91, 1633–1643.

    PubMed  CAS  Google Scholar 

  122. Stingl, G. and Maurer, D. (1997) IgE-mediated allergen presentation via Fc epsilon RI on antigen-presenting cells, Intl. Arch. Allergy Immunol., 113, 24–29.

    CAS  Google Scholar 

  123. Maurer, D., Ebner, C., Reininger, B., et al. (1995) The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation, J. Immunol., 154, 6285–6290.

    PubMed  CAS  Google Scholar 

  124. Haczku, A., Takeda, K., Hamelmann, E., et al. (1997) CD23 deficient mice develop allergic airway hyperresponsiveness following sensitization with ovalbumin, Am. J. Respir. Crit. Care Med., 156, 1945–1955.

    PubMed  CAS  Google Scholar 

  125. Breedveld, F. C. (2000) Therapeutic monoclonal antibodies, Lancet, 355, 735–740.

    Article  PubMed  CAS  Google Scholar 

  126. Presta, L. G., Lahr, S. J., Shields, R. L., et al. (1993) Humanization of an antibody directed against IgE, J. Immunol., 151, 2623–2632.

    PubMed  CAS  Google Scholar 

  127. Casale, T. B. (2001) Anti-immunoglobulin E (omalizumab) therapy in seasonal allergic rhinitis, Am. J. Respir. Crit. Care Med., 164(8), S18–S21.

    PubMed  CAS  Google Scholar 

  128. Scheinfeld, N. (2005) Omalizumab: a recombinant humanized monoclonal IgE- blocking antibody, Dermatol. Online J., 11(2), 2.

    PubMed  Google Scholar 

  129. D’Amato, G. (2006) Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases, Eur. J. Pharmacol., 533(1–3), 302–307.

    Article  PubMed  CAS  Google Scholar 

  130. Bang, L. M. and Plosker, G. L. (2004) Omalizumab: a review of its use in the management of allergic asthma, Treat. Respir. Med., 3, 183–199.

    Article  PubMed  CAS  Google Scholar 

  131. Belliveau, P. P. (2005) Omalizumab: a monoclonal anti-IgE antibody, Med. Gen. Med., 7(1), 27.

    Google Scholar 

  132. Fahy, J. V., Fleming, H. E., Wong, H. H., et al. (1997) The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects, Am. J. Respir. Crit. Care Med., 155, 1828–1834.

    PubMed  CAS  Google Scholar 

  133. Boulet, L. P., Chapman, K. R., Cote, J., et al. (1997) Inhibitory effects of an anti- IgE antibody E25 on allergen-induced early asthmatic response, Am. J. Respir. Crit. Care Med., 155, 1835–1840.

    PubMed  CAS  Google Scholar 

  134. Milgrom, H., Berger, W., Nayak, A., et al. (2001) Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab), Pediatrics, 108, E36.

    Article  PubMed  CAS  Google Scholar 

  135. Busse, W., Corren, J., Lanier, B. Q., et al. (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma, J. Allergy Clin. Immunol., 108, 184–190.

    Article  PubMed  CAS  Google Scholar 

  136. Soler, M., Matz, J., Townley, R., et al. (2001) The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics, Eur. Respir. J., 18, 254–261.

    Article  PubMed  CAS  Google Scholar 

  137. Hochhaus, G., Brookman, L., Fox, H., et al. (2003) Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma, Curr. Med. Res. Opin., 19, 491–498.

    Article  PubMed  CAS  Google Scholar 

  138. Corren, J., Casale, T., Deniz, Y., and Ashby, M. (2003) Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma, J. Allergy Clin. Immunol., 111, 87–90.

    Article  PubMed  CAS  Google Scholar 

  139. Humbert, M., Beasley, R., Ayres, J., et al. (2005) Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE, Allergy, 60, 309–316.

    Article  PubMed  CAS  Google Scholar 

  140. Bousquet, J., Cabrera, P., Berkman, N., et al. (2005) The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma, Allergy, 60, 302–308.

    Article  PubMed  CAS  Google Scholar 

  141. Noga, O., Hanf, G., and Kunkel, G. (2003) Immunological changes in allergic asthmatics following treatment with omalizumab, Intl. Arch. Allergy Immunol., 131, 46–52.

    Article  CAS  Google Scholar 

  142. Djukanovic, R., Wilson, S., Kraft, M., et al. (2004) Effects of treatment with anti- immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma, Am. J. Respir. Crit. Care Med., 170, 583–593.

    Article  PubMed  Google Scholar 

  143. Holgate, S. T., Bousquet, J., Wenzel, S., Fox, H., Liu, J., and Castellsague, J. (2001) Efficacy of omalizumab, an anti-immunoglobulin E antibody in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality, Curr. Med. Res. Opin., 17, 233–240.

    Article  PubMed  CAS  Google Scholar 

  144. Walker, S., Monteil, M., Phelan, K., Lasserson, T. J., and Walters, E. H. (2005) Anti-IgE for chronic asthma in adults and children (Cochrane Review), The Cochrane Library Issue, vol. 2, Wiley, Chichester, UK.

    Google Scholar 

  145. Casale, T. B., Busse, W. W., Kline, J. N., et al. (2006) Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis, J. Allergy Clin. Immunol., 117, 134–140.

    Article  PubMed  CAS  Google Scholar 

  146. Bousquet, J., Lockey, R., and Malling, H. J. (1998) Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper, J. Allergy Clin. Immunol., 102, 558–562.

    Article  PubMed  CAS  Google Scholar 

  147. Creticos, P. S., Reed, C. E., Norman, P. S., Khoury, J., Adkinson, N. F., Jr., et al. (1996) Ragweed immunotherapy in adult asthma, N. Engl. J. Med., 334, 501–506.

    Article  PubMed  CAS  Google Scholar 

  148. Gehlhar, K., Schlaak, M., Becker, W., and Bufe, A. (1999) Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome, Clin. Exp. Allergy, 29, 497–506.

    Article  PubMed  CAS  Google Scholar 

  149. Jutel, M., Akdis, M., Budak, F., et al. (2003) IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy, Eur. J. Immunol., 33, 1205–1214.

    Article  PubMed  CAS  Google Scholar 

  150. Nouri-Aria, K. T., Wachholz, P. A., Francis, J. N., et al. (2004) Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity, J. Immunol., 172, 3252–3259.

    PubMed  CAS  Google Scholar 

  151. Hamid, Q. A., Schotman, E., Jacobson, M. R., Walker, S. M., and Durham, S. R. (1997) Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen- induced late skin responses after successful grass pollen immunotherapy, J. Allergy Clin. Immunol., 99, 254–260.

    Article  PubMed  CAS  Google Scholar 

  152. Francis, J. N., Till, S. J., and Durham, S. R. (2003) Induction of IL- 10+CD4+CD25+ T cells by grass pollen immunotherapy, J. Allergy Clin. Immunol., 111, 1255–1261.

    Article  PubMed  CAS  Google Scholar 

  153. Adelroth, E., Rak, S., Haahtela, T., et al. (2001) Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis, J. Allergy Clin. Immunol., 106, 253–259.

    Article  Google Scholar 

  154. Casale, T, B., Condemi, J., LaForce, C., et al. (2001) Effect of omalizumab on symptoms of seasonal allergic rhinitis, J. Am. Med. Assoc., 286, 2956–2967.

    Article  CAS  Google Scholar 

  155. Chervinsky, P., Casale, T., Townley, R., et al. (2003) Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis, Ann. Allergy Asthma Immunol., 91, 160–167.

    Article  PubMed  CAS  Google Scholar 

  156. Lin, H., Boesel, K. M., Griffith, D. T., et al. (2004) Omalizumab rapidly decreases nasal allergic response and FceRI on basophils, J. Allergy Clin. Immunol., 113, 297–302.

    Article  PubMed  CAS  Google Scholar 

  157. Klunker, S., Saggar, L. R., Seyfert-Margolis, V., Asare, A. L., Casale, T. B., Durham, S. R., Francis, J. N., and the Immune Tolerance Network Group (2007) Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding, J. Allergy Clin. Immunol., 120(3), 688–695.

    Google Scholar 

  158. Casale, T. B., Busse, W. W., Kline, J. N., et al., and the Immune Tolerance Network Group (2006) Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis, J. Allergy Clin. Immunol., 117, 134–140.

    Google Scholar 

  159. Lockey, R. F., Benedict, L. M., Turkeltaub, P. C., and Bukantz, S. C. (1987) Fatalities from immunotherapy (IT) and skin testing (ST), J. Allergy Clin. Immunol., 79, 660–677.

    Article  PubMed  CAS  Google Scholar 

  160. Du Buske, L. M., Ling, C. J., and Sheffer, A. L. (1992) Special problems regarding allergen immunotherapy, Immunol. Allergy Clin. North Am., 12, 145–175.

    Google Scholar 

  161. Bukantz, S. C. and Lockey, R. F. (2004) Adverse effects and fatalities associated with subcutaneous allergen immunotherapy, Clin. Allergy Immunol., 18, 711–727.

    PubMed  CAS  Google Scholar 

  162. Tighe, H., Takabayashi, K., Schwartz, D., et al. (2000) Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity, J. Allergy Clin. Immunol., 106, 124–134.

    Article  PubMed  CAS  Google Scholar 

  163. Tighe, H., Takabayashi, K., Schwartz, D., et al. (2000) Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity, Eur. J. Immunol., 30, 1939–1947.

    Article  PubMed  CAS  Google Scholar 

  164. Marshall, J. D., Abtahi, S., Eiden, J. J., et al. (2001) Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy, J. Allergy Clin. Immunol., 108, 191–197.

    Article  PubMed  CAS  Google Scholar 

  165. Sampson, H. A (2002) Peanut allergy, N. Engl. J. Med., 346(17), 1294–1299.

    Article  PubMed  Google Scholar 

  166. Sampson, H. A. (1998) Fatal food-induced anaphylaxis, Allergy, 53(Suppl.), 125–130.

    Article  PubMed  CAS  Google Scholar 

  167. Sampson, H. A., Mendelson, L., and Rosen, J. P. (1992) Fatal and near-fatal anaphylactic reactions to food in children and adolescents, N. Engl. J. Med., 327, 380–384.

    PubMed  CAS  Google Scholar 

  168. Bock, S. A., Munoz-Furlong, A., and Sampson, H. A. (2001) Fatalities due to anaphylactic reactions to foods, J. Allergy Clin. Immunol., 107, 191–193.

    Article  PubMed  CAS  Google Scholar 

  169. Saavedra-Delgado, A. (1989) The many faces of the peanut, Allergy Proc., 10, 291–294.

    Article  PubMed  CAS  Google Scholar 

  170. Beyer, K., Morrow, E., Li, X. M., et al. (2001) Effects of cooking methods on peanut allergenicity, J. Allergy Clin. Immunol., 107, 1077–1081.

    Article  PubMed  CAS  Google Scholar 

  171. Hatahet, R., Kirch, F., Kanny, G., and Moneret-Vautrin, D. A. (1994) Sensibilisation aux allergènes d’arachide chez les nourrissons de moins de quatre mois: à propos de 125 observations, Rev. Fr. Allergol. Immunol. Clin., 34, 377–381.

    Google Scholar 

  172. Sampson, H. A. (1996) Managing peanut allergy, Br. Med. J., 312, 1050–1051.

    CAS  Google Scholar 

  173. Chiu, L., Sampson, H. A., and Sicherer, S. H. (2001) Estimation of the sensitization rate to peanut by prick skin test in the general population: results from the National Health and Nutrition Examination Survey 1988–1994 (NHANES III), J. Allergy Clin. Immunol., 107(Suppl.), S192–S192 [abstract].

    Google Scholar 

  174. Burks, W., Sampson, H. A., and Bannon, G. A. (1998) Peanut allergens, Allergy, 53, 725–730.

    PubMed  CAS  Google Scholar 

  175. Bernhisel-Broadbent, J. and Sampson, H. A. (1989) Cross-allergenicity in the legume botanical family in children with food hypersensitivity, J. Allergy Clin. Immunol., 83, 435–440.

    Article  PubMed  CAS  Google Scholar 

  176. Sicherer, S. H., Burks, A. W., and Sampson, H. A. (1998) Clinical features of acute allergic reactions to peanut and tree nuts in children, Pediatrics, 102, 131–131 [abstract].

    Google Scholar 

  177. Sicherer, S. H., Furlong, T. J., Munoz-Furlong, A., Burks, A. W., and Sampson, H. A. (2001) A voluntary registry for peanut and tree nut allergy: characteristics of the first 5149 registrants, J. Allergy Clin. Immunol., 108, 128–132.

    Article  PubMed  CAS  Google Scholar 

  178. Skolnick, H. S., Conover-Walker, M. K., Koerner, C. B., Sampson, H. A., et al. (2001) The natural history of peanut allergy, J. Allergy Clin. Immunol., 107, 367–374.

    Article  PubMed  CAS  Google Scholar 

  179. Lin, R. Y., Schwartz, L. B., Curry, A., et al. (2000) Histamine and tryptase levels in patients with acute allergic reactions: an emergency department-based study, J. Allergy Clin. Immunol., 106, 65–71.

    Article  PubMed  CAS  Google Scholar 

  180. Lack, G., Fox, D., Northstone, K., and Golding, J., for the Avon Longitudinal Study of Parents and Children Study Team (2003) Factors associated with the development of peanut allergy in childhood, N. Engl. J. Med., 348(11), 977–985 [comments: J. Fam. Pract., 52(7), 516–517 (2003); N. Engl. J. Med., 348(11), 975–976 (2003); N. Engl. J. Med., 348(11), 1946–1048 (2003); N. Engl. J. Med., 349(3), 301–303 (2003)].

    Google Scholar 

  181. Sampson, H. A. (1999) Food allergy. 2. Diagnosis and management, J. Allergy Clin. Immunol., 103, 981–989.

    Article  PubMed  CAS  Google Scholar 

  182. Simons, F. E., Gu, X., and Simons, K. J. (2001) Epinephrine absorption in adults: intramuscular versus subcutaneous injection, J. Allergy Clin. Immunol., 108, 871–873.

    Article  PubMed  CAS  Google Scholar 

  183. Oppenheimer, J. J., Nelson, H. S., Bock, S. A., Christensen, F., and Leung, D. Y. M. (1992) Treatment of peanut allergy with rush immunotherapy, J. Allergy Clin. Immunol., 90, 256–262.

    Article  PubMed  CAS  Google Scholar 

  184. Sampson, H. A. (2001) Immunological approaches to the treatment of food allergy, Pediatr. Allergy Immunol., 12(Suppl.), 14, 91–96.

    Google Scholar 

  185. Matricardi, P. M., Rosmini, F., Panetta, V., et al. (2002) Hay fever and asthma in relation to markers of infection in the United States, J. Allergy Clin. Immunol., 110,381–387.

    Article  PubMed  Google Scholar 

  186. Sampson H. (2002) Peanut allergy, N. Engl. J. Med., 346,1294–1299.

    Article  PubMed  Google Scholar 

  187. Creticos, P. S., Schroeder, J. T., Hamilton, R. G. (2006) Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis, N. Engl. J. Med., 355(14), 27–37.

    Article  Google Scholar 

  188. Cohn, L., Elias, J. A., and Chupp, G. L. (2004) Asthma: mechanisms of disease persistence and progression, Annu. Rev. Immunol., 22, 789–815.

    Article  PubMed  CAS  Google Scholar 

  189. Davies, D. E., Wicks, J., Powell, R. M., Puddicombe, S. M., and Holgate, S. T. (2003) Airway remodeling in asthma: new insights, J. Allergy Clin. Immunol., 111, 215–225.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Health & Human Services, National Institutes of Health, 6610 Rockledge Drive, Bethesda, USA

    Vassil St. Georgiev PhD

Authors
  1. Vassil St. Georgiev PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vassil St. Georgiev PhD .

Editor information

Editors and Affiliations

  1. Department of Health & Human Services, National Institutes of Health, 6610 Rockledge Drive, Bethesda, MD 20892, USA

    Vassil St. Georgiev PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Georgiev, V.S. (2009). Asthma and Allergic Diseases. In: Georgiev, V.S. (eds) National Institute of Allergy and Infectious Diseases, NIH. Infectious Disease. Humana Press. https://doi.org/10.1007/978-1-60327-297-1_45

Download citation

Publish with us

Policies and ethics

Search

Navigation